The recently published American Diabetes Association (ADA) / European Association for the Study of Diabetes (EASD) position statement on the management of hyperglycemia in type 2 diabetes (T2D) underlines the complexity of the therapeutic approach in T2D. This is due to both the increasing number of available drugs and to the paucity of solid data on the superiority of one compound over the others. TOSCA.IT is the only ongoing trial designed as a head-to-head comparison of pioglitazone versus sulfonylureas with CV end points and is also the only study, besides PROactive, evaluating the CV effects of thiazolidinediones. A previous trial (Thiazolidinedione Intervention With Vitamin D Evaluation) has been terminated prematurely because of concerns on the CV safety of rosiglitazone.
The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 Diabetes
BONORA, Enzo;
2012-01-01
Abstract
The recently published American Diabetes Association (ADA) / European Association for the Study of Diabetes (EASD) position statement on the management of hyperglycemia in type 2 diabetes (T2D) underlines the complexity of the therapeutic approach in T2D. This is due to both the increasing number of available drugs and to the paucity of solid data on the superiority of one compound over the others. TOSCA.IT is the only ongoing trial designed as a head-to-head comparison of pioglitazone versus sulfonylureas with CV end points and is also the only study, besides PROactive, evaluating the CV effects of thiazolidinediones. A previous trial (Thiazolidinedione Intervention With Vitamin D Evaluation) has been terminated prematurely because of concerns on the CV safety of rosiglitazone.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
